RRX-001

Research use only, not for human use.

RRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity.

RRX-001 (RRX001) is a novel NO and hypoxia mediated anticancer agent with with epigenetic and immunologic activity; targets CD133 + /CD44 + cancer stem cells from colon cancer cell-lines, HT-29, Caco-2, and HCT116, and inhibits Wnt pathway signalling with downregulation of c-Myc; inhibits HCT 116 and decreases levels of the DNA methyltransferases DNMT1 and DNMT3a in a time and dose-dependent manner; RRX-001 (RRX001) is a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia.Lung Cancer Phase 2 Clinical.

Cell Viability Assay Cell Line:Human MM-cell lines (MM.1S, RPMI-8226, H929, ARP1, KMS-11, OPM2, LR5, ANBL6.WT), along with drug resistant cell lines such as (MM.1R, Dox40, LR5, ANBL6.BR, RPMI-8226).Concentration:0-5 μM.Incubation Time:24 hours.Result:Induced a dose-dependent significant (p < 0.05) decrease in viability of all cell lines.

Animal Model:CB-17 SCID-mice were subcutaneously inoculated with 5.0 × 106 MM.1S cells in 100 μL of serum-free RPMI 1640 medium.Dosage:5 mg/kg or 10 mg/kg.Administration:I.V., thrice-weekly for 24 days.Result:Blocked MM tumor growth and enhances survival. Treatment was well tolerated, suggested by no apparent weight loss.Animal Model:Female BALB/c nude mice (19.2?±?1.7?g) based on A549 lung cancer model. Dosage: 10?mg/kg. Administration:IP, twice a week and once a day.Result:Resulted in the most significant tumor growth retardation.Reduction of resident macrophages in tumor-bearing mice attenuates the antitumor activity of RRx-001.

RRX001 | RRX 001

Others

Other Targets

Other Targets

Cancer

Lung Cancer

925206-65-1

268.023

C5H6BrN3O5

>98% (HPLC)

DMSO : ≥ 100 mg/mL 373.11 mM

O=[N+](C1([N+]([O-])=O)CN(C(CBr)=O)C1)[O-]

2-bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one

(-20℃)

With Ice Pack

≥ 2 years